Core Insights - Esperion reported a total revenue growth of 21% year-over-year (Y/Y) to $403.1 million for FY25, with U.S. net product revenue increasing by 38% Y/Y to $159.6 million [1][14] - The company achieved a significant Q4 2025 total revenue growth of 144% Y/Y to $168.4 million, with U.S. net product revenue also growing approximately 38% Y/Y to $43.7 million [1][14] - Esperion announced an agreement to acquire Corstasis Therapeutics, which is expected to enhance its cardiovascular franchise and align with its long-term strategic vision, Vision 2040 [1][4][3] Financial Performance - For Q4 2025, total revenue was $168.4 million, compared to $69.1 million in Q4 2024, marking a 144% increase [14] - Full-year revenue for 2025 reached $403.1 million, up from $332.3 million in 2024, reflecting a 21% increase [14] - U.S. net product sales for Q4 2025 were $43.7 million, up from $31.6 million in Q4 2024, a 38% increase [22] - Collaboration revenue for Q4 2025 was $124.7 million, a 232% increase from $37.6 million in Q4 2024 [22] Market Expansion and Strategic Initiatives - The acquisition of Corstasis Therapeutics is aimed at expanding Esperion's cardiovascular product offerings, particularly with the FDA-approved Enbumyst nasal spray [4][5] - Esperion's U.S. cardiovascular business showed strong momentum, with retail prescription equivalents growing 34% Y/Y and 11.3% quarter-over-quarter [6] - The company is focused on deeper U.S. market penetration and geographic expansion through partnerships, with a goal to enhance its product offerings and market access [3][8] Research and Development - Esperion is advancing its R&D pipeline, including the nomination of ESP-2001 for the treatment of primary sclerosing cholangitis, which represents a potential market opportunity exceeding $1 billion annually [15] - The company plans to develop oral triple combination lipid-lowering tablets, expected to be commercialized in 2027, which could rival existing therapies [10][11] Operational Highlights - Esperion's cash and cash equivalents as of December 31, 2025, totaled $167.9 million, an increase from $144.8 million in 2024 [20] - The company reported a net income of $61.8 million for Q4 2025, compared to a net loss of $21.3 million in Q4 2024 [18][19] - Selling, general, and administrative expenses for Q4 2025 were $41.4 million, a 12% increase from $36.9 million in Q4 2024, primarily due to increased legal costs [22]

Core Insights - Esperion has announced the acquisition of Corstasis Therapeutics, which developed Enbumyst, the first FDA-approved nasal spray diuretic for edema associated with congestive heart failure, hepatic, and renal diseases [1][2][4] Transaction Details - The acquisition involves an upfront cash payment of $75 million, with potential additional payments of up to $180 million based on regulatory and commercial milestones, along with low double-digit royalties on Enbumyst sales [9][10] - The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions [11] Product Overview - Enbumyst is a self-administered outpatient diuretic therapy that addresses the needs of patients with edema related to congestive heart failure, liver disease, and kidney disease [3][13] - The product targets a U.S. market opportunity exceeding $4 billion, with potential expansion into hepatic and renal indications [5][6] Strategic Rationale - The acquisition aligns with Esperion's Vision 2040, which aims to deliver innovative cardiovascular solutions to high-need patient populations [6] - Enbumyst complements Esperion's existing cardiovascular commercial infrastructure and enhances its portfolio in metabolic, hepatic, and renal diseases [6][4] Clinical Significance - The availability of Enbumyst is expected to improve patient management by providing a rapid and flexible treatment option for fluid management at home, potentially reducing hospitalizations [8][4]